[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-430177-105":59,"doc-detail-430177-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-triglycerides-in-cardiovascular-disease-prevention-evidence-mechanisms-and-emerging-therapies","Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies","","Review evaluates the evolving role of triglycerides (TGs) and TG-rich lipoproteins (TRLs) in cardiovascular disease (CVD) risk and prevention. It synthesizes mechanistic rationale, genetic and epidemiological evidence, and therapeutic potential, emphasizing residual risk in high-risk groups. Mendelian randomization and large cohorts support causality linking elevated remnant lipoproteins and atherosclerotic CVD, with apolipoprotein B as a key driver. Traditional TG-lowering shows mixed outcomes, while ApoC-III and ANGPTL3 inhibitors produce strong lipid lowering; however, outcome evidence is limited and selective PPAR modulation has not shown benefit.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-triglycerides-in-cardiovascular-disease-prevention-evidence-mechanisms-and-emerging-therapies/430177/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-triglycerides-in-cardiovascular-disease-prevention-evidence-mechanisms-and-emerging-therapies/430177.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the review’s primary goal regarding triglycerides in CVD prevention?","Question",{"text":112,"@type":113},"To evaluate how triglycerides (TGs) and TG-rich lipoproteins (TRLs) influence cardiovascular disease risk and prevention, including mechanisms, evidence, and therapeutic potential.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What evidence supports a causal link between remnant lipoproteins and atherosclerotic CVD?",{"text":117,"@type":113},"Recent Mendelian randomization studies and large clinical cohorts support a causal relationship between elevated remnant lipoproteins and atherosclerotic CVD, with apolipoprotein B described as a principal driver.",{"name":119,"@type":110,"acceptedAnswer":120},"Which emerging therapies are highlighted, and what limitation remains?",{"text":121,"@type":113},"ApoC-III and ANGPTL3 inhibitors are noted for robust lipid-lowering effects, but cardiovascular outcome data remain limited, so ongoing trials are expected to clarify meaningful protection and guideline integration.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},430177,1790909214,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Current Cardiology Reports (2026) 28:8  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1886-025-02337-1  \nCARDIOMETABOLIC DISEASE (DM AND CV) (CJ LAVIE, SECTION EDITOR)  \nTargeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies  \nUsman Alam1 · Sheetal V. Mathai1 · Annalisa Filtz1 · Toshiki Kuno2 · Juan J. Badimon3 · Allan D. Sniderman4 ·  \nSalim S. Virani5,6 · Peter P. Toth7,8 · Michael D. Shapiro9 · Carl J. Lavie10 · Deepak L. Bhatt11 · Leandro Slipczuk1,12  \nReceived: 12 November 2025 / Accepted: 9 December 2025 © The Author(s) 2026  \nAbstract  \nPurpose of Review The goal of this review is to evaluate the evolving role of triglycerides (TGs) and TG-rich lipoproteins (TRLs) in cardiovascular disease (CVD) risk and prevention. We examine the mechanistic rationale, genetic and epidemiological evidence, and therapeutic potential of targeting TGs in residual risk reduction, particularly in high-risk populations. Recent Findings Emerging data from Mendelian randomization studies and large clinical cohorts support a causal link between elevated remnant lipoproteins and atherosclerotic CVD, in which apolipoprotein B may be the principal driver. Although traditional triglyceride-lowering agents have produced mixed results on cardiovascular outcomes, emerging therapies—such as ApoC-III and ANGPTL3 inhibitors—show robust lipid-lowering effects, while selective PPAR modulatorshave thus far not demonstrated cardiovascular benefit. However, outcome data remain limited.  \nSummary Residual CVD risk persists despite aggressive LDL-C reduction, especially in patients with diabetes, metabolic syndrome, or chronic kidney disease. Selective TG-lowering strategies targeting TRLs—especially those that decrease apolipoprotein B—may provide clinical benefit in high-risk phenotypes. Ongoing trials will clarify whether these promising agents confer meaningful cardiovascular protection and warrant integration into future guidelines.  \nKeywords Triglycerides · Remnant lipoproteins · ApoC-III · ANGPTL3 · Lipid-lowering therapy  \nAbbreviations  \nACC American College of Cardiology  \nAHA American Heart Association  \nAF atrial fibrillation  \nANGPTL3/4/8 angiopoietin-like protein 3/4/8  \n􀀍 Leandro Slipczuk [lslipczukb@montefiore.org](lslipczukb@montefiore.org)  \n1 Division of Cardiology, Montefiore Health System/Albert Einstein College of Medicine, Bronx, NY, USA  \n2 Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA  \n3 Atherothrombosis Research Unit, Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA  \n4 Department of Medicine, Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, McGill University Health Centre-Royal Victoria Hospital, 1001 Boulevard Décarie, Montreal, QC, Canada  \n5 Section of Cardiology, Department of Medicine, Aga Khan University, Karachi, Pakistan  \napoB apolipoprotein B  \napoC-III apolipoprotein C-III  \nASCVD atherosclerotic cardiovascular disease  \nASO antisense oligonucleotide  \nCAC coronary artery calcium  \n6 Department of Population Health, Aga Khan University, Nairobi, Kenya  \n7 Sterling Rock Falls Clinic and CGH Medical Center, Sterling, IL, USA  \n8 Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA  \n9 Section of Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA  \n10 Ochsner Clinical School, John Ochsner Heart and Vascular Institute, The University of Queensland School of Medicine, New Orleans, LA, USA  \n11 Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA  \n12 Montefiore Medical Center, 111 E 210th St. Bronx, Bronx, NY 10467, USA  \n1 3  \nCABG  \nCAD  \nCCTA  \nCE  \nCKD  \nCM  \nCIMT  \nCVD  \nDHA  \nDM  \neGFR  \nEL  \nEPA  \nESC  \nEAS  \nEVAPORATE  \nFCS  \nFFR-CT  \nGDMT  \nHDL-C  \nHoFH  \nhs-CRPHTG ICH  \nIDL  \nIPE  \nJELIS  \nLDL  \nLDL-C  \nLDLR  \nLLT  \nLMF1  \nLPL  \nLRP","cbCaiqUcW5EaUMoU","https://ap.wps.com/l/cbCaiqUcW5EaUMoU","pdf",1617203,"English","# Abstract\n## Purpose of Review\n## Recent Findings\n## Summary\n# Keywords\n# Abbreviations","[{\"question\":\"What is the review’s primary goal regarding triglycerides in CVD prevention?\",\"answer\":\"To evaluate how triglycerides (TGs) and TG-rich lipoproteins (TRLs) influence cardiovascular disease risk and prevention, including mechanisms, evidence, and therapeutic potential.\"},{\"question\":\"What evidence supports a causal link between remnant lipoproteins and atherosclerotic CVD?\",\"answer\":\"Recent Mendelian randomization studies and large clinical cohorts support a causal relationship between elevated remnant lipoproteins and atherosclerotic CVD, with apolipoprotein B described as a principal driver.\"},{\"question\":\"Which emerging therapies are highlighted, and what limitation remains?\",\"answer\":\"ApoC-III and ANGPTL3 inhibitors are noted for robust lipid-lowering effects, but cardiovascular outcome data remain limited, so ongoing trials are expected to clarify meaningful protection and guideline integration.\"}]","Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies | PDF",1790652125,48]